AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05237882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders
Description: The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
Study NCT05405543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days
Study NCT05405543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05127200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Starstim (Neuroelectrics)
Description: Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
Study NCT05127200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Starstim (Neuroelectrics)
Description: Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
Study NCT04884074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Sleeve Gastrectomy plus Anterior Crural Repair
Description: The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
Study NCT04884074 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard sleeve gastrectomy (SSG, the control group)
Description: The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch.
Study NCT06494371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-HL30 cells
Description: Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
Study NCT04794478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom Continuous Glucose Monitoring System
Description: Dexcom Continuous Glucose Monitoring System
Study NCT04586231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Immediate-release 40 mg tablet
Study NCT04586231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsule available in 4 mg and 10 mg dosages
Study NCT04586231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Tablet available in 20 mg, 40 mg and 60 mg dosages
Study NCT06496971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: An anti-angiogenic agent to block tumor growth
Study NCT06496971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: An anti-angiogenic agent to block tumor growth
Study NCT06496971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbubble
Description: Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
Study NCT06496971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
Study NCT04419389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Acalabrutinib in CLL
Description: APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
Study NCT04419389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL
Description: APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
Study NCT04419389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
Description: APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
Study NCT04419389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
Description: APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
Study NCT04005989 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal Cells Injection
Description: Adipose stromal cell
Study NCT04005989 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Stromal Cells Injection
Description: Adipose stromal cell
Study NCT04910373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Extensively Hydrolyzed Formula
Description: experimental powder formula
Study NCT04910373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Extensively Hydrolyzed Formula
Description: placebo powder formula
Study NCT05408468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMCOPE-ICU
Description: (1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
Study NCT04145479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: exercise
Study NCT06479993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Description: Supplementation with chlorella (6g/day for 3-weeks)
Study NCT06479993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)
Study NCT04298151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconomer Improved
Description: glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
Study NCT04298151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Molar quick Aplicap
Description: highly viscous glass ionomer with improved mechanical properties than the conventional GI
Study NCT05832957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drive fun
Description: The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills.
Study NCT05832957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: 7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
Study NCT05832957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: one-time short guidance on safe driving at the end of the study.
Study NCT05796843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 360 Degrees virtual reality-based mirror therapy
Description: Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
Study NCT05796843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mirror therapy
Description: Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
Study NCT05796843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
Study NCT05796843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
Study NCT06492252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: To assess functional connectivity patterns between regions that predict learning.
Study NCT06492252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech
Study NCT06492252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory baseline in speech
Study NCT05588492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin-containing regimen
Description: Rifamycin-containing regimen
Study NCT05588492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin-free regimen
Description: Rifamycin-free regimen
Study NCT06025058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
Study NCT06025058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
Study NCT04713020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention:APP educational programs
Description: Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
Study NCT04713020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention:general care
Description: general care
Study NCT06446739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
Study NCT06446739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
Study NCT05029427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High molecular weight β-glucan oat cookies
Description: Two cookies that contains 4g beta glucan made from oats will be consumed per day.
Study NCT05029427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control wheat based cookies
Description: Two cookies that made from cream of wheat without beta glucan will be consumed per day.
Study NCT05023174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal Hernia Repair with Platelet Rich Plasma
Description: Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
Study NCT05023174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hiatal Hernia Repair without Platelet Rich Plasma
Description: Surgery will be performed without the addition of platelet rich plasma injection
Study NCT05818345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pricing intervention
Description: Participants will be provided with a menu with manipulated prices for products with lower kilocalories
Study NCT05612100 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05612100 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete alopecia questionnaires
Study NCT05612100 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete alopecia surveys
Study NCT04373668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Medication Review
Description: A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
Study NCT04373668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Sleep Hygiene
Description: Training module on the principle of good sleep hygiene
Study NCT05205993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion
Description: A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Study NCT05205993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
Study NCT05205993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
Study NCT05447858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SWEA
Description: Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
Study NCT05447858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck-specific exercise
Description: NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
Study NCT04693715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 injection solution
Study NCT04693715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection solution
Study NCT05289453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lens extraction by phacoemulsification
Description: lens extraction by phacoemulsification
Study NCT05676398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory rhythm recording
Description: Ambulatory rhythm recording by use of a wearable patch-type device.
Study NCT05757349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-down position time 1-day
Description: Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
Study NCT05757349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-down position time 3-day
Description: Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
Study NCT05685407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
Study NCT05685407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
Study NCT04645030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultra low-dose computer thermography
Description: The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and >25 to insure optimal ULD-CT image quality.
Study NCT04645030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior.
Study NCT06017232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid telerehabilitation program
Description: The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics.